Oncimmune announces new contract with global pharma company
The contract concerns profiling Immunoglobulin E autoantibodies in blood serum
Read Moreby PharmaTimes | Aug 19, 2024 | News | 0
The contract concerns profiling Immunoglobulin E autoantibodies in blood serum
Read Moreby Jen Brogan | Aug 16, 2024 | News | 0
The study yielded over one million dose-responsive curves for existing cancer drugs
Read Moreby Jen Brogan | May 16, 2024 | News | 0
The OptiZest study aims to investigate a personalised dose of Zestril in these patients
Read Moreby Lucy Parsons | Jun 16, 2021 | News | 0
Allcyte specialises in artificial intelligence (AI) based precision medicine
Read Moreby Lucy Parsons | Apr 12, 2021 | News | 0
Experimental drug plus immunotherapy demonstrated early potential in aggressive brain cancer
Read Moreby Lucy Parsons | Sep 16, 2020 | News | 0
Researchers found combination treatment showed promise against a range of cancer types
Read Moreby Anna Smith | Sep 20, 2019 | News | 0
only 7% of children with targetable mutations were able to access the appropriate adult drug in a study.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
